Literature DB >> 8093564

"Neutral allografts"--lack of allogeneic stimulation by cultured human cells expressing MHC class I and class II antigens.

V A Theobald1, J D Lauer, F A Kaplan, K B Baker, M Rosenberg.   

Abstract

Cultured human dermal fibroblasts, smooth muscle cells, epidermal cells and endothelial cells were tested for immunogenicity in an in vitro allostimulation assay. Gamma interferon was used to induce MHC class II expression, since these cells constitutively express class I but not class II antigens. In contrast to human dermal fibroblasts, smooth muscle cells and epidermal cells, endothelial cells, were able to stimulate a significant proliferative response in normal allogeneic lymphocytes. Since ICAM-1 was also expressed on these cells, this inability to initiate allostimulation was probably not due to the absence of adhesion molecules. Addition of exogenous cytokines such as IL-1, IL-2, and TNF did not restore T cell proliferation in the test system. Therefore the inability of dermal fibroblasts, smooth muscle cells, and epidermal cells to initiate significant allostimulation was also not due to lack of cytokine production. It appears that certain cells lack as-yet-undefined costimulatory factors required for their effective recognition as foreign. These results support the notion that cultured human fibroblasts, smooth muscle cells, and epidermal cells could serve as building blocks of engineered "neutral allografts" for use across MHC barriers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093564     DOI: 10.1097/00007890-199301000-00024

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Endovascular treatment of experimental aneurysms by use of biologically modified embolic devices: coil-mediated intraaneurysmal delivery of fibroblast tissue allografts.

Authors:  W E Marx; H J Cloft; G A Helm; J G Short; H M Do; M E Jensen; D E Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2001-02       Impact factor: 3.825

Review 2.  Antigen-presenting cell engineering. The molecular toolbox.

Authors:  M L Tykocinski; D R Kaplan; M E Medof
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

3.  StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds: results from a prospective, randomized, controlled dose escalation trial.

Authors:  John M Centanni; Joely A Straseski; April Wicks; Jacquelyn A Hank; Cathy A Rasmussen; Mary A Lokuta; Michael J Schurr; Kevin N Foster; Lee D Faucher; Daniel M Caruso; Allen R Comer; B Lynn Allen-Hoffmann
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

4.  Ultrastructural evidence for blood microvessels devoid of an endothelial cell lining in transplanted pancreatic islets.

Authors:  A Lukinius; L Jansson; O Korsgren
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

5.  DNA microarray-based gene expression profiling in porcine keratocytes and corneal endothelial cells and comparative analysis associated with xeno-related rejection.

Authors:  Mee Kum Kim; Joo Youn Oh; Jung Hwa Ko; Hyun Ju Lee; Jin Ho Jung; Won Ryang Wee; Jin Hak Lee; Chung-Gyu Park; Sang Joon Kim; Curie Ahn; Seung-Jun Kim; Seung Yong Hwang
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

6.  Separate developmental programs for HLA-A and -B cell surface expression during differentiation from embryonic stem cells to lymphocytes, adipocytes and osteoblasts.

Authors:  Hardee J Sabir; Jan O Nehlin; Diyako Qanie; Linda Harkness; Tatyana A Prokhorova; Blagoy Blagoev; Moustapha Kassem; Adiba Isa; Torben Barington
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

7.  Immunogenicity of undifferentiated and differentiated allogeneic mouse mesenchymal stem cells.

Authors:  Blessing Mukonoweshuro; Christopher Jf Brown; John Fisher; Eileen Ingham
Journal:  J Tissue Eng       Date:  2014-04-29       Impact factor: 7.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.